Form 4: Moderna President Stephen Hoge Reports Stock Transactions

Moderna President Stephen Hoge reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• Stephen Hoge, President of Moderna, Inc., reported changes in his beneficial ownership of company stock.
• On August 29, 2025, 651 restricted stock units (RSUs) converted into common stock on a one-for-one basis.
• Concurrently, 315 shares were disposed of at $24.47 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Hoge directly owns 1,453,512 shares of common stock.
• He also indirectly owns 4,116 shares through Valhalla, LLC and 151,933 shares through a trust for his spouse and children.
• Hoge retains 1,304 unvested restricted stock units, which are scheduled to vest in twelve equal quarterly installments following March 1, 2023.

Sentiment

Score: 6

Explanation: The filing reports routine executive compensation events, specifically the vesting of restricted stock units and the subsequent sale of shares to cover tax obligations. This indicates continued executive retention and the execution of a pre-defined compensation plan, which is generally a neutral to slightly positive signal regarding management stability.

Positives

• The vesting of restricted stock units indicates continued compensation and retention of a key executive.
• The acquisition of 651 shares of common stock through RSU conversion increases direct ownership, even with tax-related sales.

Negatives

• Disposition of 315 shares to cover tax obligations, while common, represents a reduction in direct shareholding.

Future Outlook

The filing indicates a continued vesting schedule for Stephen Hoge's restricted stock units, with the remaining 1,304 units vesting in twelve equal quarterly installments following March 1, 2023.

Management Comments

• The reporting person disclaims Section 16 beneficial ownership of these securities [held by trust], except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

Industry Context

This Form 4 filing is a routine disclosure of executive compensation and share ownership changes, common across all publicly traded companies. It reflects the standard practice of granting restricted stock units as part of executive compensation packages and the subsequent tax-related sales upon vesting. It does not provide specific insights into Moderna's operational performance or broader industry trends beyond executive compensation practices.

Comparison to Industry Standards

• The RSU vesting and subsequent tax-related sale are standard practices in executive compensation across the biotechnology and pharmaceutical industries.
• Companies like Pfizer (PFE), Johnson & Johnson (JNJ), and AstraZeneca (AZN) also utilize similar equity compensation structures for their executives, where a portion of vested shares is often sold to cover tax liabilities.
• The reported transactions are consistent with typical insider activity related to equity awards.

Stakeholder Impact

• Shareholders: Provides transparency into executive share ownership and compensation practices. The sale of shares for tax purposes is a common occurrence and not indicative of a lack of confidence.
• Employees: Reflects the company's executive compensation structure, which may influence broader employee compensation strategies.

Next Steps

• Continued vesting of the remaining 1,304 restricted stock units in twelve equal quarterly installments.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events, specifically the vesting of restricted stock units and the subsequent sale of shares to cover tax obligations. Such transactions are common and do not typically signal a change in the company's fundamental outlook or the executive's confidence. Therefore, it provides no new information that would warrant a change in an existing investment thesis, leading to a 'hold' recommendation based solely on this filing.

Keywords

Moderna, MRNA, Stephen Hoge, Insider Trading, Form 4, Restricted Stock Units, Stock Vesting, Executive Compensation, Share Ownership